The Role of Oncology-Focused CROs for Clinical Research Organizations
The role of cancer-focused clinical research organizations (CROs) has become more apparent with the increased number of cancer clinical trials. Oncology clinical trials are conducted worldwide and are designed to assist sponsors create their Veristat oncology trial design in a practical, timely manner. CROs with niche expertise in oncology —commonly small and mid-sized CROs— provide clinical trial sponsors with an attractive set of strategic advantages and practical benefits. Some of the advantages provided by CROs with oncology experience include;
Contacts key opinion leaders in oncology (KOLs)
A cancer trial’s quality will be improved by relying on the clinical experience of well-respected medical oncologists. Finding key opinion leaders (KOLs) in the cancer type being examined has many benefits in oncology clinical trial design, procedure insights, study design, and recruiting potential. Expert medical oncologists are often in close communication with CROs that manage oncology trials. Therefore, they can bring them on board to offer scientific value to your research.
Collaborates with Cancer Clinical Site Networks
Having the best cancer centers in each participating city or country is an objective that must be met when conducting international research. That’s as important as having cancer KOLs participate is critical. Cancer-focused CROs can point you in the direction of the best recruiting hospitals in their areas, thus saving you time. When selecting the appropriate hospitals and clinics for your oncology trial, a respected CRO partner will save you the effort, time and money, which is especially crucial if your study seeks to recruit patients with rare malignancies.
Thorough understanding of the condition
Clinical trial success relies heavily on a thorough understanding of the condition under study. As such, clinical research associates and other CRO professionals should have prior experience in handling cancer studies to ensure that critical study features are not neglected. A clinical data manager with expertise in cancer studies, for example, can determine if an electronic case report form (eCRF) is appropriately designed to capture accurate tumor data and cancer therapy data.
CROs Role in Phase 1 Cancer Clinical Trials
CROs specialized in cancer can help ensure fast patient recruitment and high-quality data in early phase or phase 1 oncology trials. To begin with, oncology CROs have worked with clinical sites to recruit cancer patients for early-phase trials. Also, phase 1 trials in oncology have two primary goals: to assess medication safety and define the maximum tolerated dosage (MTD), which is used to determine the recommended dose for phase 2 investigations (RP2D).
CROs Role in Phase 3 Cancer Clinical Trials
In an international scenario, CROs can identify an influential network of cancer centers. Phase 3 or pivotal clinical trials necessitate the participation of many hospitals, which is especially true when the trial targets rare cancers. To finish the study in a fair amount of time, the sponsor may require at least four or five countries. The sponsor will save time and money by utilizing these already established sites networks to which CROs have access.
CROs help sponsors easily execute phase I-IV oncology trials. Along with expert medical oncologists, CROs frequently collaborate to develop an effective treatment for cancer patients. For instance, in phase 1 cancer trials, CROs can help assure quick recruitment and easy access to high-quality data. They can also help you find a good network of cancer centers, especially if your trial is international.